Alternative immunomodulators.
There is now a large number of potential immunomodulatory agents that may be of value in inflammatory bowel disease. The newer immunosuppressants, such as tacrolimus and mycophenolate, probably offer little more than providing comparable alternatives to more established agents, and fish oil and other eicosanoid modulators are probably not especially potent if effective. The biological agents, however, bring a more novel and potentially powerful approach. Natalizumab, and targeted mucosal delivery of interleukin-10 already show considerable promise.